相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events
Fatiha H. Shabaruddin et al.
PHARMACOECONOMICS (2013)
Nursing Takes Time: Workload Associated With Administering Cancer Protocols
Johan de Raad et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2010)
A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer
John W. Tumeh et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Societal preference values for advanced melanoma health states in the United Kingdom and Australia
K. M. Beusterien et al.
BRITISH JOURNAL OF CANCER (2009)
Cost-Effectiveness Analysis of Lapatinib in HER-2-Positive Advanced Breast Cancer
Quang A. Le et al.
CANCER (2009)
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
Konstantin J. Dedes et al.
EUROPEAN JOURNAL OF CANCER (2009)
Are adverse effects incorporated in economic models? An initial review of current practice
D. Craig et al.
HEALTH TECHNOLOGY ASSESSMENT (2009)
Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
Nicole Mittmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
The Economic Value of Primary Prophylaxis Using Pegfilgrastim Compared with Filgrastim in Patients with Breast Cancer in the UK
Zhimei Liu et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2009)
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model
Sixten Borg et al.
ACTA ONCOLOGICA (2008)
Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients
Sung-Hsin Kuo et al.
BREAST (2008)
Guideline Implementation for Breast Healthcare in Low- and Middle-income Countries: Treatment Resource Allocation
Alexandru Eniu et al.
CANCER (2008)
Medical Resource Utilizations and Economic Burden in Chinese Cancer Patients with Chemotherapy-induced Anemia: A Populational Database Study
Chieh-Yu Liu et al.
CHINESE JOURNAL OF CANCER RESEARCH (2008)
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis
Sorrel E. Wolowacz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)
Josh J. Carlson et al.
LUNG CANCER (2008)
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the US
David H. Henry et al.
SUPPORTIVE CARE IN CANCER (2008)
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
Adi Eldar-Lissai et al.
VALUE IN HEALTH (2008)
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
Jonathan Karnon et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2008)
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
M. Lidgren et al.
ANNALS OF ONCOLOGY (2008)
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
Lieven Annemans et al.
SUPPORTIVE CARE IN CANCER (2008)
Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of 3 alternative theories
William Dale et al.
MEDICAL DECISION MAKING (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis
Robert E. Bristow et al.
GYNECOLOGIC ONCOLOGY (2007)
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
Nancy A. Risebrough et al.
CANCER (2007)
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
Thomas E. Delea et al.
CLINICAL BREAST CANCER (2007)
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
Jonas Lundkvist et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients
Charles L. Bennett et al.
ONCOLOGIST (2007)
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany
Florian Lordick et al.
EUROPEAN JOURNAL OF CANCER (2007)
Economic burden of haematological adverse effects in cancer patients - A systematic review
S. Y. Liou et al.
CLINICAL DRUG INVESTIGATION (2007)
Methodological issues in the economic analysis of cancer treatments
Paul Tappenden et al.
EUROPEAN JOURNAL OF CANCER (2006)
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
BE Hillner et al.
CANCER (2005)
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
J Norum et al.
ANNALS OF ONCOLOGY (2005)
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis
G Dranitsaris et al.
SUPPORTIVE CARE IN CANCER (2005)
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
V Caggiano et al.
CANCER (2005)
Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors
A Minisini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea
G Dranitsaris et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy
LE Cosler et al.
PHARMACOTHERAPY (2004)
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
BV Fortner et al.
BMC CANCER (2004)
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
GH Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain
B Ojeda et al.
BRITISH JOURNAL OF CANCER (2003)
Balancing the benefits and costs of colony-stimulating factors: A current perspective
GH Lyman
SEMINARS IN ONCOLOGY (2003)
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy
SB Cantor et al.
CANCER (2003)
Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies
MC Weinstein et al.
VALUE IN HEALTH (2003)
Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods
N Graves et al.
HEALTH ECONOMICS (2002)
Changing patient perceptions of the side effects of cancer chemotherapy
N Carelle et al.
CANCER (2002)
Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients
EA Calhoun et al.
ONCOLOGIST (2001)
分享论文
